Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 8/20 | 0.72 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.72 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.72 |
| ▸ | NOS1 | P29475 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.59 |
| ▸ | METAP2 | P50579 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29741144 | 1.00 | FGFR1 (0.72) | FGFR1FGFR2FGFR3NOS1MAPT | |
| Fumaric Acid SCHEMBL6361834 | 0.86 | FGFR1 (0.57) | FGFR1FGFR2FGFR3NOS1MAPT | |
| Fumaric Acid SCHEMBL6361838 | 0.86 | FGFR1 (0.57) | FGFR1FGFR2FGFR3NOS1MAPT | |
| SCHEMBL14663812 | 0.84 | FGFR1 (1.00) | FGFR1FGFR2FGFR3NOS1MAPT | |
| SCHEMBL29520931 | 0.83 | ROCK2 (0.59) | FGFR1FGFR2FGFR3NOS1MAPT | |
| SCHEMBL277777 | 0.83 | ROCK2 (0.59) | FGFR1FGFR2FGFR3NOS1MAPT | |
| Hydrochloric Acid SCHEMBL27782875 | 0.81 | ROCK2 (0.57) | FGFR1FGFR2FGFR3NOS1MAPT | |
| SCHEMBL29741168 | 0.79 | FGFR1 (0.49) | FGFR1FGFR2FGFR3NOS1MAPT | |
| SCHEMBL24046742 | 0.74 | NOS1 (0.59) | FGFR1FGFR2FGFR3NOS1MAPT | |
| SCHEMBL9529035 | 0.74 | NOS1 (0.59) | FGFR1FGFR2FGFR3NOS1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 532 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3386511-B2 | METHODS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2024-03-20 | — | — | EP | claimed |
| CN-116102566-A | Preparation method and application of indazole-modified rhodamine mercury ion probe | 上海前瞻创新研究院有限公司 | 2023-05-12 | — | — | CN | claimed |
| EP-3814357-A1 | HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2021-05-05 | — | — | EP | claimed |
| CN-107987057-A | The preparation method of Axitinib and its intermediate | 王兆举 | 2018-05-04 | — | — | CN | claimed |
| CN-105734586-B | A kind of organic-silicon-modified corrosion inhibitor and preparation method thereof | 中国石油化工股份有限公司 | 2018-04-10 | — | — | CN | claimed |
| US-9486892-B2 | Polishing composition | FUJIMI INCORPORATED (JP) | 2016-11-08 | — | — | US | claimed |
| CN-105734586-A | Organosilicon-modified corrosion inhibitor and preparation method thereof | 中国石油化工股份有限公司 | 2016-07-06 | — | — | CN | claimed |
| CN-104523682-A | Application of 6-hydroxy-1-hydro-indazole in preparation of medicine for preventing and treating neurodegenerative disease | WANG WENYA | 2015-04-22 | — | — | CN | claimed |
| US-20090039811-A1 | Inhibitors of HSP90 | CHENE PATRICK | 2009-02-12 | — | — | US | claimed |
| CN-101027053-A | Hsp90 inhibitor | NOVARTIS AG (CH) | 2007-08-29 | — | — | CN | claimed |
| WO-2007071686-A1 | COMPOSITION FOR DYEING KERATIN FIBRES WITH A TETRAAZAPENTAMETHINE CATIONIC DIRECT DYE, AN OXIDATION BASE AND A PARTICULAR COUPLER | L'ORÉAL (FR) | 2007-06-28 | — | — | WO | claimed |
| EP-1773327-A1 | INHIBITORS OF HSP90 | Novartis AG (CH) | 2007-04-18 | — | — | EP | claimed |
| WO-2006010595-A1 | INHIBITORS OF HSP90 | NOVARTIS AG (CH) | 2006-02-02 | — | — | WO | claimed |
| US-20040231067-A1 | Dyeing composition comprising a cationic tertiary para-phenylenediamine and heterocyclic coupler, methods and uses | L'OREAL (FR) | 2004-11-25 | — | — | US | claimed |
| EP-1428510-A1 | Dyeing composition comprising a tertiary paraphenylenediamine containing a pyrrolidine, and a heterocyclic coupler or a hydroxybenzamide ; method and use | L'OREAL (FR) | 2004-06-16 | — | — | EP | claimed |
| US-4168953-A | Oxidation hair dyes based upon tetraaminopyrimidine developers and monohydroxyindazole couplers | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (HENKEL KGAA) (DE) | 1979-09-25 | — | — | US | claimed |
| EP-4743079-A2 | APOL1 INHIBITORS AND METHODS OF USE THEREOF | Maze Therapeutics, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4720038-A1 | (HETERO)ARYL-CARBONYL-HETEROBICYCLIC COMPOUNDS AS INHIBITORS OF PMS2 FOR CANCER AND DEGENERATIVE ILLNESSES | Neophore Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| US-3939142-A | Phenylazophenyl dyestuff | HOECHST AKTIENGESELLSCHAFT (DT) | 1976-02-17 | — | — | US | disclosed |
| US-3939084-A | Functional fluid compositions containing substituted pyrimidines | MONSANTO COMPANY (US) | 1976-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040231067-A1 | Dyeing composition comprising a cationic tertiary para-phenylenediamine and heterocyclic coupler, methods and uses | KRT18, CDC73, PYCR1 | FGFR1 1023/4885FGFR2 861/4885FGFR3 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.